Publication:
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024

Simple item page
dc.contributor.authorMaurel, Marine
dc.contributor.authorHoward, Jennifer
dc.contributor.authorKissling, Esther
dc.contributor.authorPozo Sanchez, Francisco
dc.contributor.authorPérez-Gimeno, Gloria
dc.contributor.authorBuda, Silke
dc.contributor.authorSève, Noémie
dc.contributor.authorMcKenna, Adele
dc.contributor.authorMeijer, Adam
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorMlinarić, Ivan
dc.contributor.authorLatorre-Margalef, Neus
dc.contributor.authorTúri, Gergő
dc.contributor.authorLazar, Mihaela
dc.contributor.authorMazagatos, Clara
dc.contributor.authorEcheverria, Aitziber
dc.contributor.authorAbela, Stephen
dc.contributor.authorBourgeois, Marc
dc.contributor.authorMachado, Ausenda
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorPetrović, Goranka
dc.contributor.authorOroszi, Beatrix
dc.contributor.authorJancoriene, Ligita
dc.contributor.authorMarin, Alexandru
dc.contributor.authorHusa, Petr
dc.contributor.authorDuffy, Róisín
dc.contributor.authorDijkstra, Frederika
dc.contributor.authorGallardo García, Virtudes
dc.contributor.authorGoerlitz, Luise
dc.contributor.authorEnouf, Vincent
dc.contributor.authorBennett, Charlene
dc.contributor.authorHooiveld, Mariëtte
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorTrobajo-Sanmartín, Camino
dc.contributor.authorVišekruna Vučina, Vesna
dc.contributor.authorSamuelsson Hagey, Tove
dc.contributor.authorLameiras Azevedo, Ana Sofía
dc.contributor.authorCastilla, Jesús
dc.contributor.authorXuereb, Gerd
dc.contributor.authorDelaere, Bénédicte
dc.contributor.authorGomez, Verónica
dc.contributor.authorTolksdorf, Kristin
dc.contributor.authorBacci, Sabrina
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorKaczmarek, Marlena
dc.contributor.authorRose, Angela Mc
dc.contributor.authorEuropean IVE group
dc.contributor.funderUnión Europea. European Centre for Disease Prevention and Control (ECDC)
dc.date.accessioned2024-03-22T10:36:45Z
dc.date.available2024-03-22T10:36:45Z
dc.date.issued2024-02
dc.description.abstractInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipThe ‘Vaccine Effectiveness, Burden and Impact Studies’ (VEBIS) is a project of the European Centre for Disease Prevention and Control (ECDC) run under the framework contract No. ECDC/2021/019 (EU-PC) and ECDC/2021/016 (EU-H).es_ES
dc.format.number8es_ES
dc.format.page2400089es_ES
dc.format.volume29es_ES
dc.identifier.citationEuro Surveill. 2024 Feb;29(8):2400089.es_ES
dc.identifier.doi10.2807/1560-7917.ES.2024.29.8.2400089es_ES
dc.identifier.e-issn1560-7917es_ES
dc.identifier.journalEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletines_ES
dc.identifier.pubmedID38390651es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19055
dc.language.isoenges_ES
dc.publisherEuropean Centre for Disease Prevention and Control (ECDC)
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/ECDC/2021/019es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/ECDC/2021/016es_ES
dc.relation.publisherversionhttps://doi.org/10.2807/1560-7917.ES.2024.29.8.2400089es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectEuropees_ES
dc.subjectInfluenzaes_ES
dc.subjectMulticentre studyes_ES
dc.subjectTest-negative designes_ES
dc.subjectVaccine effectivenesses_ES
dc.subject.meshInfluenza Vaccineses_ES
dc.subject.meshInfluenza, Humanes_ES
dc.subject.meshInfluenza A Virus, H1N1 Subtypees_ES
dc.subject.meshHumanses_ES
dc.subject.meshInfluenza B viruses_ES
dc.subject.meshInfluenza A Virus, H3N2 Subtypees_ES
dc.subject.meshVaccinationes_ES
dc.subject.meshCase-Control Studieses_ES
dc.subject.meshSeasonses_ES
dc.subject.meshHospitalses_ES
dc.subject.meshPrimary Health Carees_ES
dc.titleInterim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024es_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication5611ffc3-de88-4908-b20a-9a15a58c060a
relation.isAuthorOfPublicationcd6d5fea-c769-479f-bdfa-1f76888459a3
relation.isAuthorOfPublicatione177bf8c-3734-480b-a2ae-4ae67491776c
relation.isAuthorOfPublication7ac13a7f-3d30-4846-8b51-b7505c7df45c
relation.isAuthorOfPublication.latestForDiscovery5611ffc3-de88-4908-b20a-9a15a58c060a
relation.isFunderOfPublication78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isFunderOfPublication.latestForDiscovery78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isPublisherOfPublication844b1441-479c-4219-87e5-efc493160a02
relation.isPublisherOfPublication.latestForDiscovery844b1441-479c-4219-87e5-efc493160a02

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Interim2023_24_Influenza_A_Vaccine_2024.pdf
Size:
653.99 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Centro Nacional de Epidemiología (CNE)
Centro Nacional de Microbiología (CNM)
IdiSNA - Instituto de Investigación Sanitaria de Navarra (Navarra)